Seres Therapeutics announces three-year research collaboration with AstraZeneca.
Seres Therapeutics (MCRB) announced a three-year research collaboration with AstraZeneca (AZN). The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds. Under the collaboration, research will evaluate microbiome-based approaches as a predictor for which patients may respond best to certain cancer immunotherapies. Additionally, SER-401, an investigational microbiome therapeutic, may be studied in combination with AstraZeneca compounds targeting various cancers. The collaboration will apply Seres' microbiome drug discovery and manufacturing expertise with AstraZeneca's extensive oncology experience to evaluate the potential for microbiome therapy to improve clinical response when used in conjunction with adjunctive pharmaceutical approaches. Under the terms of the exclusive collaboration, AstraZeneca will provide Seres with $20M in three equal installments over two years, with the first payment due at the start of the agreement. In addition, AstraZeneca will also reimburse Seres for research activity related to the collaboration. Seres will maintain rights to oncology targeted microbiome therapeutic candidates, and AstraZeneca will obtain the option to negotiate for rights to those programs and other inventions arising out of the collaboration.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 11, 2019|
|Previous Article:||Treasury 3-year auction outlook: the $38 B sale is the first of three.|
|Next Article:||Integra LifeSciences manufacturing facility received warning letter from FDA.|